Ian Somaiya's most recent trade in NewAmsterdam Pharma Company NV was a trade of 60,216 Ordinary Shares done at an average price of $9.3 . Disclosure was reported to the exchange on Jan. 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.26 per share. | 20 Jan 2026 | 60,216 | 118,598 | - | 9.3 | 557,600 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 60,216 | 702,598 | - | - | Option (Right to Buy) | |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 39,784 | 662,814 | - | - | Option (Right to Buy) | |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.26 per share. | 20 Jan 2026 | 39,784 | 98,166 | - | 9.3 | 368,400 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.78 per share. | 20 Jan 2026 | 39,712 | 77,986 | - | 31.8 | 1,262,047 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.80 per share. | 20 Jan 2026 | 24,362 | 58,382 | - | 33.8 | 823,436 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.38 per share. | 20 Jan 2026 | 19,604 | 58,382 | - | 32.4 | 634,778 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.25 per share. | 20 Jan 2026 | 15,422 | 82,744 | - | 33.3 | 512,782 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.64 per share. | 20 Jan 2026 | 900 | 117,698 | - | 30.6 | 27,576 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2026 | 115,000 | 115,000 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2026 | 25,500 | 58,382 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.25 per share. | 05 Jan 2026 | 5,118 | 32,882 | - | 33.3 | 170,174 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 46,983 | 777,714 | - | - | Option (Right to Buy) | |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.26 per share. | 27 Jan 2025 | 46,983 | 84,983 | - | 9.3 | 435,063 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 33,679 | 51,304 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 14,900 | 762,814 | - | - | Option (Right to Buy) | |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.26 per share. | 27 Jan 2025 | 14,900 | 52,900 | - | 9.3 | 137,974 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 13,304 | 38,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 11,495 | 41,405 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 3,405 | 38,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 38,000 | 38,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 220,000 | 220,000 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 80,000 | 80,000 | - | - | Option (right to buy) |